Raptor Pharmaceutical Corp. (RPTP) reported quarterly earnings results on Thursday, Aug-4-2016. The company said it had a profit of $-0.16 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.01. Analysts had a consensus of $-0.17. The company posted revenue of $32.05 million in the period, compared to analysts expectations of $28.51 million. The company’s revenue was up 37.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.17 EPS.
Raptor Pharmaceutical Corp. closed down -0.13 points or -2.14% at $5.94 with 4,02,261 shares getting traded on Tusday. Post opening the session at $6.04, the shares hit an intraday low of $5.8 and an intraday high of $6.1236 and the price fluctuated in this range throughout the day.Shares ended Tusday session in Red.
In a different news, on Sep 11, 2015, Suzanne Louise Bruhn (director) sold 18,258 shares at $12.47 per share price. According to the SEC, on Sep 4, 2015, Raymond Anderson (director) sold 4,916 shares at $12.51 per share price. On Jul 2, 2015, Llew Keltner (director) sold 50,000 shares at $16.05 per share price, according to the Form-4 filing with the securities and exchange commission.
Raptor Pharmaceutical Corp. is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by rare and debilitating diseases. The Company’s product PROCYSBI delayed-release capsules received marketing approval from the FDA for the management of nephropathic cystinosis in adults and children six years and older. In Europe PROCYSBI gastro-resistant hard capsules of cysteamine received a marketing authorization from the European Commission (EC) as an orphan medicinal product for the management of nephropathic cystinosis in the European Union (EU). The Company’s pipeline includes its delayed-release form of cysteamine or RP103 and its oral 4-methylpyrazole or Convivia. Its other product Quinsair is an inhaled formulation of levofloxacin used for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.